Chimeric alkaline phosphatase-like proteins

• US 9,926,544 B2
• Filed: 01/26/2015
• Issued: 03/27/2018
• Est. Priority Date: 01/24/2014
• Status: Active Grant

• Current Assignee: AM-Pharma B.V.
• Original Assignee: AM-Pharma B.V.
• Inventors: Raaben, Willem, Jonk, Luigi Johannes Cornelius, Van Den Berg, Erik Jan, Van Elsas, Andrea, Milln, Jos Luis
• Primary Examiner(s): Mondesi, Robert B
• Assistant Examiner(s): Epstein, Todd M
• Application Number:
  US15/113,696
• Publication Number:
  US 20170009216A1
• Time in Patent Office: 1,156 Days
• Field of Search: None
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 9/16 acting on ester bonds (3.1)
• CPC Class Codes: C12Y 301/00 Hydrolases acting on ester bonds (3.1)
• CPC Class Codes: C12Y 301/03001 Alkaline phosphatase (3.1.3.1)

Abstract

The invention relates to improved alkaline phosphatases, pharmaceutical compositions comprising improved alkaline phosphatases and the use of improved alkaline phosphatases for preventing, treating or curing diseases.

Claims

1. An isolated protein having phosphatase activity comprising the amino acid sequence set forth in SEQ ID NO:

1.

2. The isolated protein of claim 1 which comprises a glycosylation site.

3. The isolated protein of claim 1, wherein the isolated protein has a higher affinity for pyridoxal 5′

-phosphate (PLP) at physiological pH than an alkaline phosphatase having the amino acid sequence of SEQ ID NO;

4.

4. The isolated protein of claim 1, wherein the amino acid sequence of the isolated protein consists of the sequence of SEQ ID NO:

1.

5. The isolated protein of claim 4 which comprises a glycosylation site.

6. A composition comprising the isolated protein of claim 1 and a pharmaceutical acceptable carrier, a diluent or an excipient.

7. A composition comprising the isolated protein of claim 4 and a pharmaceutical acceptable carrier, a diluent or an excipient.

8. The composition of claim 7 which is a fluid or a solid.

10. The composition of claim 8, wherein the solid is a capsule, a tablet, or a powder.

11. The composition of claim 6 which is a nutritional composition or a nutraceutical.

12. A polynucleotide comprising a nucleic acid sequence encoding a protein according to claim 1.

13. A vector comprising a polynucleotide according to claim 12.

14. The vector of claim 13 which is a cloning or expression vector.

15. A polynucleotide comprising a nucleic acid sequence encoding a protein according to claim 4.

16. A vector comprising a polynucleotide according to claim 15.

17. The vector of claim 16 which is a cloning or ion vector.

9. The composition 8, wherein the fluid is an injectable fluid, an infusion fluid, an elixir, a syrup, or a suspension.